Covid-19: Russia says its Sputnik V vaccine is 95% effective

Published by Manon C. · Published on 24 November 2020 at 18h37 · Updated on 25 November 2020 at 11h23
The race for vaccine is escalating. After the Pfizer and BioNTech, Moderna and AstraZeneca laboratories, Russia claims their Covid-19 vaccine, Sputnik V, is 92% effective.

Two days after the Pfizer and BioNTech laboratories announced their vaccine was “95% effective, after AstraZeneca said theirs was 90% effective, and Moderna's was 94.5% effective, Russia puts itself back into the race and announced today its candidate vaccine called Sputnik V is 95% effective instead of the 92% announced this past November 11.

Developed by the Gamaleya institute, the Russian vaccine have been in lots of talks over the past months. Praised by Vladimir Putin himself, the vaccine already delivered encouraging results, as medical journal The Lancet reported in an article released on September 4, 2020.

The release in The Lancet is a meaningful response to skeptics who unreasonably criticized the Russian vaccineRussian sovereign fund director entrusted with developing and marketing the vaccine Kirill Dmitriev said.

This past November 11, the Russian Investment Fund says that in the 16,000 participants to the Sputnik V vaccine clinical trial, 20 have caught coronavirus. The Russian sovereign fund adds the risk of catching the virus was below 92% in people vaccinated with their vaccine, in comparison with those who have been inoculated a placebo.

Today, Tuesday November 24, the Gamaleya laboratory announces that according to preliminary results, the Sputnik V vaccine is 95% effective. These results have been achieved on volunteers 42 days after inoculating the first dose, the Russian Health Minister and the Russian Investment Fund announced. Russian scientists entrusted with developing the vaccine have also announced their research will be released shortly "in one of the main medical magazines in the world reviewed by peers".

Furthermore, the Russian Investment Fund says in the release that "The cost of one dose of the Sputnik V vaccine for international markets will be less than $10" and it will be free for Russian citizens.

But marketing the Sputnik V vaccine is not possible for the time being. As a matter of fact, the Russian trials are to take place for at least 6 more months.

This is yet good news for the search of the oh-so awaited vaccine and another step in the fight against coronavirus.

Practical information

Refine your search
Refine your search
Refine your search
Refine your search